A deal will include milestone payments to manage risk along the way. The deal might be 500M, but will only be a small amount up front, with further payments with positive P3 results and FDA marketing approval etc. So they will only pay the full amount for a drug that makes it to market.
Royalties will form an important part of the deal providing Neuren with a long term funding model to support other developments and use applications (eg TBI).
We are lucky to have Dr T with so much experience in this area.
A deal will include milestone payments to manage risk along the...
-
- There are more pages in this discussion • 184 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$20.23 |
Change
0.125(0.62%) |
Mkt cap ! $2.579B | |||
| Open | High | Low | Value | Volume |
| $20.39 | $20.43 | $20.14 | $624.7K | 30.80K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 532 | $20.21 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.23 | 42 | 5 |
View Market Depth
| Last trade - 11.10am 26/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |